Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!

Human DNAM-1/CD226 Protein

Human DNAM-1/CD226 Protein

CAT#: ICP-A018

Inquiry

Overview Specification

Species	Human
Tag	C-His-Avi
Expression Systems	Expi293
Keywords	Human; C-His-Avi; Expi293

Synonyms	CD226 molecule; CD226; DNAM1; PTA1; TLiSA1
Background	DNAX accessory molecule-1 (DNAM-1), also known as CD226, is a 65 kDa type I transmembrane glycoprotein in the immunoglobulin superfamily. DNAM-1 mediates cellular adhesion to other cells bearing its ligands, CD112 and CD155, and cross-linking DNAM-1 with antibodies causes cellular activation. Furthermore, DNAM-1 can interact with PVR and PVRL2.
Source	Recombinant Human DNAM-1/CD226 Protein is expressed from Expi293 with His tag and Avi tag at the C-terminal. It contains Glu19-Asn247.
Molecular Weight	The protein has a predicted MW of 28.9 kDa. Due to glycosylation, the protein migrates to 45-70 kDa based on Tris-Bis PAGE result.
Endotoxin	Less than 1 EU per μg by the LAL method.
Purity	>95% as determined by Tris-Bis PAGE. >95% as determined by HPLC.
Formulation	Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 5% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80℃ for 12 months as supplied from the date of receipt. -20 to -80℃ for 3-6 months in an unopened state after reconstitution. 2-8℃ for 2-7 days after reconstitution.
Notes	Recommend to aliquot the protein into smaller quantities for optimal storage. Please avoid freeze-thaw cycles.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Online Inquiry

Alfa Cytology provides its clients with one-stop solutions to accelerate therapeutic discovery and development of brain tumors.

By Disease

Craniopharyngioma

Schwannoma (neuroma)

Pituitary Tumors

Choroid Plexus Tumors

By Molecule Type

Small Molecule Drug

Therapeutic Antibody

Immune Cell Therapy

Oncolytic Virotherapy

Vaccine Development

Contact Us

Copyright © 2024 Alfa Cytology. All rights reserved.